Phreesia, Inc. (NYSE:PHR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Phreesia, Inc. (NYSE:PHR – Get Rating) have earned an average rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $42.07.

Several brokerages have recently issued reports on PHR. Citigroup dropped their target price on shares of Phreesia from $36.00 to $23.00 and set a “neutral” rating on the stock in a research report on Friday, June 3rd. SVB Leerink dropped their target price on shares of Phreesia from $29.00 to $22.00 and set a “market perform” rating on the stock in a research report on Friday, June 3rd. JMP Securities dropped their target price on shares of Phreesia from $50.00 to $34.00 and set a “market outperform” rating on the stock in a research report on Friday, June 3rd. Raymond James dropped their target price on shares of Phreesia from $45.00 to $34.00 in a research report on Monday, June 6th. Finally, Royal Bank of Canada dropped their target price on shares of Phreesia from $29.00 to $20.00 in a research report on Monday, June 6th.

Phreesia Stock Up 3.2 %

PHR stock opened at $26.44 on Friday. The firm has a market cap of $1.38 billion, a PE ratio of -8.58 and a beta of 0.81. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.93 and a current ratio of 4.93. The firm’s fifty day moving average is $22.70 and its 200 day moving average is $25.18. Phreesia has a one year low of $13.19 and a one year high of $76.10.

Phreesia (NYSE:PHR – Get Rating) last released its quarterly earnings results on Thursday, June 2nd. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.10. The company had revenue of $63.35 million for the quarter, compared to analyst estimates of $62.24 million. Phreesia had a negative net margin of 69.40% and a negative return on equity of 36.36%. The firm’s revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.24) earnings per share. On average, research analysts forecast that Phreesia will post -3.94 EPS for the current year.

Insiders Place Their Bets

In other Phreesia news, General Counsel Allison C. Hoffman sold 3,909 shares of Phreesia stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $17.07, for a total transaction of $66,726.63. Following the transaction, the general counsel now directly owns 115,099 shares of the company’s stock, valued at $1,964,739.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Gillian Munson sold 2,605 shares of the business’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $25.59, for a total value of $66,661.95. Following the sale, the director now directly owns 21,550 shares of the company’s stock, valued at approximately $551,464.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Allison C. Hoffman sold 3,909 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $17.07, for a total transaction of $66,726.63. Following the completion of the sale, the general counsel now directly owns 115,099 shares in the company, valued at $1,964,739.93. The disclosure for this sale can be found here. Insiders have sold 12,964 shares of company stock valued at $295,194 over the last ninety days. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Nichols & Pratt Advisers LLP MA grew its holdings in shares of Phreesia by 10.8% in the second quarter. Nichols & Pratt Advisers LLP MA now owns 61,495 shares of the company’s stock valued at $1,538,000 after purchasing an additional 5,975 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Phreesia by 19.9% in the second quarter. Envestnet Asset Management Inc. now owns 11,621 shares of the company’s stock valued at $291,000 after purchasing an additional 1,929 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Phreesia by 42.2% in the second quarter. Assetmark Inc. now owns 1,685 shares of the company’s stock valued at $42,000 after purchasing an additional 500 shares in the last quarter. Brown Advisory Inc. grew its holdings in shares of Phreesia by 31.6% in the second quarter. Brown Advisory Inc. now owns 2,169,860 shares of the company’s stock valued at $54,488,000 after purchasing an additional 520,457 shares in the last quarter. Finally, US Bancorp DE grew its holdings in shares of Phreesia by 6.6% in the second quarter. US Bancorp DE now owns 8,270 shares of the company’s stock valued at $207,000 after purchasing an additional 509 shares in the last quarter. 94.29% of the stock is owned by hedge funds and other institutional investors.

Phreesia Company Profile

(Get Rating)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments.